Identifier to cite or link to this item: http://hdl.handle.net/20.500.13003/14219
Mediterranean Diet Decreases the Initiation of Use of Vitamin K Epoxide Reductase Inhibitors and Their Associated Cardiovascular Risk: A Randomized Controlled Trial
Identifiers
DOI: 10.3390/nu12123895
eISSN: 2072-6643
WOS ID: 000602367100001
Scopus EID: 2-s2.0-85098259145
PMID: 33352771
Embase PUI: L2005673306
Share
Statistics
Item usage statisticsMetadata
Show Dublin Core item recordAuthor
Castro-Barquero, Sara; Ribo-Coll, Margarita; Lassale, Camille; Tresserra-Rimbau, Anna; Castaner, Olga; Pinto, Xavier; Angel Martinez-Gonzalez, Miguel; Sorli, Jose, V; Salas-Salvado, Jordi; Lapetra, Jose; Gomez-Gracia, Enrique; Alonso-Gomez, Angel M.; Fiol Sala, Miquel

Publication date
2020-12Document type
research articleCitation
Castro-Barquero S, Ribo-Coll M, Lassale C, Tresserra-Rimbau A, Castaner O, Pinto X, et al. Mediterranean Diet Decreases the Initiation of Use of Vitamin K Epoxide Reductase Inhibitors and Their Associated Cardiovascular Risk: A Randomized Controlled Trial. Nutrients. 2020 Dec;12(12):3895.Abstract
Our aim is to assess whether following a Mediterranean Diet (MedDiet) decreases the risk of initiating antithrombotic therapies and the cardiovascular risk associated with its use in older individuals at high cardiovascular risk. We evaluate whether participants of the PREvencion con DIeta MEDiterranea (PREDIMED) study allocated to a MedDiet enriched in extra-virgin olive oil or nuts (versus a low-fat control intervention) disclose differences in the risk of initiation of: (1) vitamin K epoxide reductase inhibitors (acenocumarol/warfarin; n = 6772); (2) acetylsalicylic acid as antiplatelet agent (n = 5662); and (3) other antiplatelet drugs (cilostazol/clopidogrel/dipyridamole/ditazol/ticlopidine/triflusal; n = 6768). We also assess whether MedDiet modifies the association between the antithrombotic drug baseline use and incident cardiovascular events. The MedDiet intervention enriched with extra-virgin olive oil decreased the risk of initiating the use of vitamin K epoxide reductase inhibitors relative to control diet (HR: 0.68 [0.46-0.998]). Their use was also more strongly associated with an increased risk of cardiovascular disease in participants not allocated to MedDiet interventions (HRcontrol diet: 4.22 [1.92-9.30], HRMedDiets: 1.71 [0.83-3.52], p-interaction = 0.052). In conclusion, in an older population at high cardiovascular risk, following a MedDiet decreases the initiation of antithrombotic therapies and the risk of suffering major cardiovascular events among users of vitamin K epoxide reductase inhibitors.
Publisher version
https://dx.doi.org/10.3390/nu12123895Keywords
Mediterranean Dietrandomized controlled trials
prevention
4-hydroxycoumarins
platelet aggregation inhibitors
This item appears in following Docusalut collections
Hospital Universitario Son Espases - HUSE > Comunicación científicaInstituto de Investigación Sanitaria Islas Baleares - IDISBA > Comunicación científica